RIOMET Stays on Shelves: FDA Greenlights Diabetes Med Continuity
Published Date: 3/13/2025
Notice
Summary
The FDA says RIOMET oral solution (metformin) hasn’t been pulled from the market because of safety or effectiveness problems. This means generic versions can keep getting approved as long as they follow the rules. Patients and drug makers can keep counting on this medicine without any sudden changes or costs.
Analyzed Economic Effects
2 provisions identified: 2 benefits, 0 costs, 0 mixed.
Generics Can Still Be Approved
The FDA found that RIOMET (metformin hydrochloride) Oral Solution, 500 mg/5 mL has not been withdrawn for safety or effectiveness. Because of that, the FDA will continue to approve abbreviated new drug applications (ANDAs) that refer to this product as long as they meet legal and regulatory requirements.
Patients Can Rely on Drug Availability
The FDA determined RIOMET (metformin hydrochloride) Oral Solution, 500 mg/5 mL was not withdrawn for safety or effectiveness, and it will not begin procedures to withdraw approvals of ANDAs that refer to this drug. You (patients who use this medicine) can expect continued access and stability for this product without sudden regulatory withdrawal.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Take It Personal
Get Your Personalized Policy View
Start a Free Government Policy Watch to see how policy affects your household, then upgrade to PRIA Full Coverage for year-round monitoring.
Already have an account? Sign in